Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7952W HIGH $6.30
Volume
3.02 K
Value Traded
10.20 K
Short % Float
0.64%
0%Week
-36.85%1 Month
+3.33%3 Month
-4.75%6 Month
-84.04%5 Year
-13.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
464.47 M
EPS (TTM)
-2.32
P/E Ratio
-
Ent. Value
6.44 B
Total Shares
153.89 M
Float Shares
785.87 M
Insiders
-
Institutions
5.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
OPT Catalyst Timeline
Dated clinical, regulatory and corporate events for Opthea Limited
Past FDA Catalysts and PDUFA Decisions
How OPT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every OPT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| sozinibercept Fast Track | wet AMD | Phase 3 | 2025-03-31 | 4 week dosing: mean change bcva 13.3, n 301, ranibizumab mean change 14.2, p value 0.35; 8 week dosing: mean change bcva 12.9, n 301, ranibizumab mean change 14.2, p value 0.19; overall population 4 week: mean change bcva 13.3, n 328, ranibizumab mean change 14.3, p value 0.32; overall population 8 week: mean change bcva 12.6, n 326, ranibizumab mean change 14.3, p value 0.09Read More | Opthea Announces Decision to Discontinue Wet AMD TrialsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in OPT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0 % | - | 2.09 M |
Ownership Trends
OPT Short Interest
Shares sold short, counted twice a month.
0.64%
Short % of Float
of tradable shares sold short
537.8K
Shares Sold Short
0.0% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
0
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How OPT ranks across every disease it competes in
Competitive Position is a premium feature
See how OPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialOPT News
About Opthea Limited
Founded2020
BIOPHARMAWATCH ELITE PLUS
Trade the next OPT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime